Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors ...(treatment of advanced kidney cancer and ...),Health

About S*BIO Pte Ltd

S*BIO is a privately-held biotechnology company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer. The company's lead programs focus on histone deacetylases (HDAC) and kinases. S*BIO has an established R&D infrastructure that is complemented by a clinical development team. In addition, S*BIO has links with a network of medical oncologists in Asia Pacific. More information about S*BIO can be found at www.sbio.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding potential clinical applications for SB1518 and SB1578, the potential for their development and commercialization, the clinical development, regulatory processes, and commercialization efforts related to Nexavar and Onyx's expectation that it will be profitable on a non-GAAP basis for the 2008 fiscal year. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on forward-looking statements
'/>"/>